cyrilzakka/clinical-trials huggingface dataset:
Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer

The investigators hope that after this research, two different treatment methods' curative effects for advanced gastric cancer can be assessed. One is continuous use of apatinib, the other is 5 days' continuous use and 2 days' off of apatinib.


Eligibility Criteria:
Inclusion Criteria:

1. Male and female patients,age≥18years
2. Confirmed by Pathology or histology of Gastric cancer
3. Patients who failed first-line chemotherapy
4. The ECOG physical status score:0 to 2
5. Expected survival ≥3months
6. Patients should be voluntary to the trail and provide with signed informed consent.
7. The researchers believe patients can benefit from the study.

Exclusion Criteria:

1. Pregnant or lactating women
2. Patients with a knowm history of allergic reactions and/ou hypersensitivity attributed to apatinib or its accessories
3. Patients with apatinib contraindications
4. Patients of doctors considered unsuitable for the trail
The Physiological Impact of N95 Masks on Medical Staff

Wearing N95 masks may have adverse physical effect on medical staff

Wearing N95 masks results in hypooxygenemia and hypercapnia which reduce working efficiency and the ability to make correct decision.

Medical staff are at increased risk of getting 'Severe acute respiratory syndrome'(SARS), and wearing N95 masks is highly recommended by experts worldwide. However, dizziness, headache, and short of breath are commonly experienced by the medical staff wearing N95 masks. The ability to make correct decision may be hampered, too. The purpose of the study was therefore to evaluate the physiological impact of N95 mask on medical staff.

Eligibility Criteria:
Inclusion Criteria:

* medical staff

Exclusion Criteria:

* pregnancy
EEG Brain-Machine Interface Control of an Upper-Limb Robotic Exoskeleton for Robot-Assisted Rehabilitation After Stroke

The goal of this study is to develop a clinically feasible, low-cost, nonsurgical neurorobotic system for restoring function to motor-impaired stroke survivors that can be used at the clinic or at home. Moreover, another goal is to understand how physical rehabilitation assisted by robotic device combined with electroencephalograph (EEG) can benefit adults who have had stroke to improve functions of their weaker arm.

The proposed smart co-robot training system (NeuroExo) is based on a physical upper-limb robotic exoskeleton commanded by a non-invasive brain machine interface (BMI) based on scalp EEG to actively include the participant in the control loop .

The study will demonstrate that the Neuroexo smart co-robot arm training system is feasible and effective in improving arm motor functions in the stroke population for their use at home.The NeuroExo study holds the promise to be cost-effective patient-centered neurorehabilitation system for improving arm functions after stroke.

This study has two phases: The first phase will consist of baseline recordings for system calibration and training sessions to be conducted in a clinical setting. The second phase will consist of NeuroExo BMI-exo neurotherapy to be conducted at the participant's home. Throughout the study and after completion of the study, movement and brain activity will be analyzed to assess function of the affected upper extremity and changes in brain activity associated with the neurotherapy.

Eligibility Criteria:
Inclusion Criteria:

* subjects between the ages of 20-65, male or female,
* mild-to- moderate unilateral stroke confirmed by brain CT or MRI scan and manifested by a Glasgow Coma scale (GCS) score between 15 and 9 documented within 6 months,
* the ability to perform 20deg of active wrist/elbow for upper limb robotic movement on the affected side, no planned alteration in lower/upper- extremity therapy/medication for muscle tone during course of study,
* Anticipated length of needed acute interdisciplinary rehabilitation of 30 days or more.
* Patients are required to have a MMSE\>=24 to rule out those with cognitive impairments.
* Patients will have to have normal/near normal strength in one upper/lower extremity and appreciable weakness in the other upper/lower extremity.

Exclusion Criteria:

* history of traumatic brain injury prior to the current episode,
* Severe neurologic or psychiatric condition preventing participation in rehabilitation and physical therapy activities (patients unable or unwilling to receive instruction and effectively complete a simple assigned task as determined by MMSE\>=24 specified in inclusion criteria).
* Women and minorities will be recruited as long as they meet the inclusion criteria.
Umbilical Cord-derived Mesenchymal Stem Cell Exosomes on Hair Growth in Patients With Androgenetic Alopecia

A total of 50 patients with androgenetic alopecia were selected for the study. Patients who met the inclusion/exclusion criteria were randomly assigned to groups A and B in a 1:1 ratio to receive treatment, with the enrollment date designated as Day 1. Group A visited the clinic once each in the first, second, and third months for treatment with exosomes, while Group B visited the clinic twice each in the first, second, and third months for treatment with exosomes. At the time points of 1, 2, 3, and 6 months after the start of the treatment period, dermatoscopic examinations were conducted on patients in both groups. The differences in hair growth density, hair shaft thickness, and follicle counts within a 1 cm diameter area were compared between the two groups. Additionally, the data differences for each subject at baseline and at the end of the experiment were also assessed.


Eligibility Criteria:
Inclusion Criteria:Clinical diagnosis of Androgenic alopecia · AGA classification include：The No grade for male hair loss was II-V, and the Ludwig grade for female hair loss was I-III Exclusion Criteria: (1) Using medications or supplements, including finasteride, dutasteride, minoxidil or any other hormonal products, that can affect hair growth; · (2) Patients with severe diseases, immune diseases, endocrine diseases and nervous system diseases; (3) Patients with infection, allergic disease and malignant tumor
Efficacy of a Modified Banxia Xiexin Decoction for the "Wei-Pi" Syndrome (Postprandial Distress Syndrome)

The study aims to evaluate the efficacy of a modified Banxia Xiexin Decoction (BXD) for Wei-Pi through a randomized, waitlist controlled trial.

After being informed about the study plan, potential risk and benefits, all subjects will give written informed consent prior to participation and undergo eligibility screening. Eligible participants will be randomized, in a 1:1 ratio, into BXD group and waitlist group.

Eligibility Criteria:
Inclusion Criteria:

* Permanent resident of Hong Kong with age from 18 to 60
* Have a diagnosis of Wei-Pi (postprandial distress syndrome, ie. at least one of bothersome postprandial fullness (ie, severe enough to impact on usual activities) and bothersome early satiation (ie, severe enough to prevent finishing a regular-size meal) at least three days per week for the last three months, with symptom onset at least six months before diagnosis

Exclusion Criteria:

* Pregnancy or pregnancy planners
* Abnormal liver function (up to twofold the upper normal reference level of ALT)\[14\] or kidney function (estimated creatinine clearance \< 80 mL/min)\[15\]
* History of diagnosed gastric structural abnormalities through endoscopy /History of gastric removal surgery
* Have G6PD deficiency
* Alcohol or drug abuser
* Taking Chinese medicine within one month
* Unable to read/understand and sign the informed consent document
Preoperative and Intraoperative Quantification of Axillary Tumoral Load

At present, patients diagnosed of a breast cancer with infiltration of the axillary lymph-nodes are submitted to axillary lymph-node dissection (ALND). The sentinel node (SN) technique is not indicated when a lymph-node biopsy or cytology is positive, nor when the surgical treatment is upfront neither when a neoadjuvant systemic therapy is indicated. The reason for not performing SN is that patients diagnosed of an infiltrated axilla though ultrasound-guided biopsy or cytology tend to have a higher tumoral load than those diagnosed after a sentinel biopsy. Furthermore, even if these patients are submitted to a neoadjuvant systemic treatment and the axillary clinical exploration is negative after the treatment, different studies showed that the SN false negative rate is unacceptably high.

Despite these facts, a high proportion of patients with a positive axilla at diagnosis and submitted to level I and II axillary lymph node dissection show few lymph nodes infiltrated in the pathological study, frequently four or less neoplastic nodes. New methods of detecting these patients with limited infiltrated nodes should be developed and new approaches to axillary surgery (i.e., partial resection) should be offered.

To date, the only information expected to get after an axillary imaging is performed is if the axilla is infiltrated or not. No information about the tumoral load is demanded. In the other hand, level I and II ALND is performed according to established anatomic limits, without selecting the nodes to be excised neither identifying the ones infiltrated for a directed excision.

The aim of the study is to evaluate the ability of a specified and reproducible imaging protocol for distinguishing patients with a high axillary tumoral load from the ones with a low tumoral load. At the same time, as the initial nodes receiving lymph drainage should be the ones commonly affected, identifying these nodes injecting diluted methylene blue in the retroareolar parenchyma and studying their tumoral load could help selecting patients with high from those with low axillary tumoral load.

Evaluation of both steps (that is, first the imaging protocol followed by the methylene blue protocol), could eventually help to distinguish which patients should be submitted to a classical level I and II ALND and which ones can be spared from excising the lymph nodes not stained by the methylene blue.


Eligibility Criteria:
Inclusion Criteria:

* Breast cancer patients with infiltrated axillary lymph nodes cT1-4 cN1
* Older than 18 years old
* Able to understand and accept the protocol procedure and to sign an informed consent form in accordance with national legislation.

Exclusion Criteria:

* Breast cancer patients in whom no information about axillary lymph nodes status (cytology or biopsy) is available.
* Patients younger than 18 years old.
* Psychiatric disease
* Difficulties to understand Spanish.
Clinical Assessment of Visual Function With the Acrysof ReSTOR Multifocal IOL

An unmasked trial after bilateral implantation of AcrySof® ReSTOR®, SA60D3 IOL . Enrolled are at least 30 patients or as much as possible from the doctor's clinical practice perspective. 6 months follow-up after IOL implant in the 2nd eye


Eligibility Criteria:
Inclusion Criteria:

* Able to complete all required postoperative visits; Planned cataract removal by phaco; 21 years of age or older, either gender or any race; potential postoperative visual acuity of 20/20; astigmatism ≦1.0D measured by keratometry in study eye(s);clear int

Exclusion Criteria:

* Signs of capsular tear, significant anterior chamber hyphema;zonular rupture; corneal pathology and refractive surgery;hypercritical patient; patients with unrealistic expectations in post-op VA; happy to wear glasses;occupational night drivers
Ultrasound-guided Inguinal Field Block (Genitofemoral, Iliohypogastric and Ilioinguinal Nerve Block) for Inguinal Hernia Surgery

The purpose of this study is to investigate the analgesic efficacy of an ultrasound-guided inguinal field block (block of the genitofemoral, iliohypogastric and ilioinguinal nerve).

Inguinal hernia repair accounts for 10-15% of all operations in general surgery. Moderate to severe pain can occur at the first day after inguinal hernia repair in 25% of patients at rest and in 60% during activity. On day 6 after the operation the incidence can be as high as 11% at rest and 33% during activity.

Ultrasound imaging for regional anesthesia techniques have improved the success and safety rate of nerve blocks. We hypothesized that a procedure consisting of an ultrasound-guided inguinal field block (genitofemoral, iliohypogastric and ilioinguinal nerve block and incision line infiltration) could effectively control postoperative pain compared to selective unilateral subarachnoid anesthesia.

Eligibility Criteria:
Inclusion Criteria:

* BMI (Body mass index) \< 30
* Non severe liver, renal or cardiac disease
* No allergy or contraindications to any of the study drugs
* American Hernia Society Score type I-II-IV-V hernia
* No pain or chronic analgesic administration in the preoperative period
* No previous surgery of the inguinal region
* Normal coagulation parameters and platelet count (\> 100.000).
* Dicumarol and aspirin suspension for \> 7 days
* Correctly administrated premedication
* No systemic infections
* No contraindications to subarachnoid anesthesia

Exclusion Criteria:

* BMI (Body mass index) \> 30
* Severe liver, renal or cardiac disease
* Allergy or contraindications to any of the study drugs
* American Hernia Society Score type III-VI-VII-0 hernia
* Pain or chronic analgesic administration in the preoperative period
* Previous surgery of the inguinal region
* Anormal coagulation parameters and platelet count (\< 100.000).
* No dicumarol and aspirin suspension for \> 7 days
* Incorrectly administrated premedication
* Systemic infections
* Contraindications to subarachnoid anesthesia
Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma

The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.


Eligibility Criteria:
Inclusion Criteria:

* request for cryopreserved ovarian tissue transplantation;
* premature ovarian failure or irregular mentrual cycles;
* negative test for HIV, HBV, HCV, Treponema pallidum;
* negative PAP test;
* oncological authorization;
* absence of neoplastic contamination in the cryopreserved ovarian tissue;
* Informed consent

Exclusion Criteria:

* neoplastic contamination in cryopreserved ovarian tissue;
* history of endometriosis;
* endocrinological disorders present and not treated (uncompensated thyroid dysfunction, diabetes (type 1, type 2);
* body mass index (BMI) \>30 kg/m2;
* circulating platelet level \< 150,000 / mml;
* bacterial infection;
* ongoing use of anticoagulants;
* bleeding diathesis.
Individualized rTMS for Motor Recovery in Stroke Patients

This study aimed to aim to investigate the efficacy of individualized rTMS according to lateralization index on motor recovery and cortical excitability in subacute stroke patients.

Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology.

High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode.

However, the current rTMS studies for stroke patients utilized the same therapeutic protocol and there is no individualized rTMS protocol based on the value of lateralization index.

This study aimed to aim to investigate the efficacy of individualized rTMS according to lateralization index on motor recovery and cortical excitability in subacute stroke patients.

Eligibility Criteria:
Inclusion Criteria:

1. Unilateral ischemic or hemorrhagic stroke
2. Stroke within 3 months
3. Medical Research Council Scale for Muscle Strength in upper limb ≤ 3
4. No previous stroke, seizure, dementia, Parkinson's disease or other degenerative neurological diseases.
5. Patient could sit over 15 minutes
6. Age over 20

Exclusion Criteria:

1. Previous stroke, traumatic brain injury, brain tumor
2. With central nervous system disease (spinal cord injury, Parkinson's disease)
3. Any contraindication to rTMS (seizure, alcoholism, metal implant, pacemaker)
4. Patients unable to cooperate the treatment
5. Pregnancy
6. Depression
Isothiocyanates and Metabolic Health

Many sprouts, for example broccoli sprouts, contain substances that have shown to have protective effects, both against oxidative stress and against carcinogenic substances.

In this study we will investigate the activation of the body's antioxidant defense system and effect on blood lactate and glucose after 1 week of isothiocyanate rich sprout supplementation. The subjects will perform maximal and submaximal work test, blood sampling, muscle biopsies and blood pressure monitoring post supplementation. We hypothesize that 1 week of supplementation of isothiocyanate rich sprouts alters blood lactate and glucose metabolism and activates the body's antioxidant defense system.

Many sprouts, for example broccoli sprouts, contain high levels of glucosinolates, which can be converted to the bioactive substances isothiocyanates. This conversion is assisted by another plant enzyme, myrosinase, which is released when the plant is mechanically processed. It is believed that this reaction is part of the plant's natural defense against pest insects and other animals that attack the plant in the early developmental stage. In cell and animal studies supplementation with isothiocyanates has been shown to induce the protein Nrf2 which is a so-called "Master regulator" of the body's antioxidant defenses and activates more than 200 genes that together provide a strong protection against oxidative and mutagenic stress.

In this study we will investigate Nrf2 activation in human skeletal muscle and effect on lactate-, glucose metabolism after 1 week of isothiocyanate rich sprout supplementation. The study is a double-blinded, randomized, placebo controlled, cross-over study with 4 weeks wash-out between the interventions. We will perform maximal- and submaximal work test and monitor blood glucose and lactate during the tests. Also, in the post intervention phases we will perform muscle biopsies, glucose tolerance tests and monitor blood pressure.

The hypothesis is that 1 week of isothiocyanate rich sprout supplementation activates Nrf2 in human skeletal muscle and alters blood lactate and glucose metabolism in rest and during exercise.

Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteer
* 18-45 years old

Exclusion Criteria:

* Any chronic disease
* Inability to perform cycling exercise
* Allergic to anesthesia
Birth Environment and Childbirth-stress, Control & Outcome

This research improves the correlation between birth control and birth outcomes by understanding the childbirth environment and birth stress. A Quasi Experiment research . The sample size was calculated using a two-tailed test, the significance level α was 0.05, the power was 80%, three groups of repeated measurements were taken three times, the effect size (effect size) was set to medium.25, and the required number of samples was 108 people, resulting in a 20% wastage rate, a total of 129 people are needed, so each of the three groups is expected to accept 43 people.


Eligibility Criteria:
Inclusion Criteria:

1. Be at least 20 years old,
2. Those who agree to participate in this research and can read and write Chinese,
3. vaginal delivery
4. Those who have no high-risk complications or chronic diseases during pregnancy and childbirth.

Exclusion Criteria:

1. Those who have been diagnosed with mental illness by a doctor, including those with depression and mood disorders
2. Exclude stillbirths and newborns with congenital abnormalities
Mathematically Arterialised Testing of Hypercapnic Subjects Study

Prospective observational cohort study of patients admitted to hospital with suspected hypercapnic respiratory failure and requiring treatment with non-invasive ventilation (NIV) as part of standard, routine management. Contemporaneous blood gas samples will be obtained via arterial, capillary, and venous methods. The venous samples will undergo mathematical arterialisation via the v-TAC system. In line with standard medical care, arterial samples will be obtained before starting NIV and at two set points afterwards (day 1 post-NIV, and pre-discharge). Pre-existing clinical thresholds will be used to assess the reliability of v-TAC against ABG, the existing gold standard and will conduct a retrospective model of decision-making once the blood sampling component of the study is concluded.


Eligibility Criteria:
Inclusion Criteria:

* Aged 18 years or above.
* Admitted for consideration of home Non Invasive Ventilation.
* Due to undergo arterial blood gas sampling as part of routine clinical care

Exclusion Criteria:

* Inability to provide informed consent.
* Clinical necessity to perform blood gas sampling prior to allowing sufficient time for informed consent.
* Inability to obtain reliable SpO2 readings
Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

The primary objective of this trial is to determine whether treatment with tiotropium (18 mcg) capsule once daily via the HandiHaler reduces the proportion of patients with COPD experiencing an exacerbation and the proportion of patients hospitalized for an exacerbation during a six month observation period.


Eligibility Criteria:
Pharmacokinetics of Midazolam When Co-administered With HEC74647 and HEC110114

This is a single center, open-label study to investigate whether HEC74647 and HEC110114 has an effect on the pharmacokinetic (PK) profile of midazolam（a cytochrome (CYP) 3A4 substrate）in healthy subjects

This is a single center, open-label study in healthy adult subjects. Total 14 subjects will be enrolled into the study and will be receive study drug per the defined treatment.

Eligibility Criteria:
Inclusion Criteria:

* Sign the informed consent form before the trial and fully understand the contents of the trial, the process and possible adverse reactions.
* Be able to complete the study according to the trail protocol.
* Subjects (including partners) have no pregnancy plan within 3 months after the last dose of study drug and voluntarily take effective contraceptive measures.
* Must be male or female between 18 to 45 years of age inclusive.
* Male and female should weigh no less than 50 kg and 45 kg respectively, and body mass index (BMI) between 18 and 28 kg /m2, inclusive.
* Physical examination and vital signs without clinically significant abnormalities.

Exclusion Criteria:

* Use of \>5 cigarettes per day during the past 3 months.
* Known history of allergy to study drugs#or allergies constitution ( multiple drug and food allergies
* History of alcohol abuse (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits or 100 mL of wine).
* Donation or loss of blood over 450 mL within 3 months prior to screening.
* 12-lead ECG with clinically significant.
* Positive for Viral hepatitis (including hepatitis B and C), HIV and syphilis.
* Subjects deemed unsuitable by the investigator for any other reason.